The Seattle biotech that gained approval last week for the first cancer vaccine in the US is riding its wave of success all the way to a bigger and better facility.

Dendreon announced yesterday that its moving headquarters and local operations to a new, four-story, 200,000 square-foot building on the Seattle waterfront, the Seattle Times reports.

But the company will have bigger fish to fry than the ones being thrown around the city’s famed Pike Place market. Dendreon will need to ramp up capacity at its three factories in New Jersey, California and Georgia if it hopes to meet its sale forecasts of $1.2 to $2.5 billion worth of Provenge prostate-cancer vaccine per year. In the coming year, the biotech expects to sell 2,000 treatments for $93,000 a pop while its New Jersey plant runs at one-quarter capacity and the other two factories are still in construction.

Image of Pike Place Market by kyhuskers2 via Flickr Creative Commons